Cyclica

Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Cloud, Clostridioides difficile infection, SALT, Chemistry, Development, CCM, Patient, ESG, SVP, DGX, Software, Partnership, Therapy, AXIN1, Drug discovery, Pharmacokinetics, Research, Genentech, International Conference on Information Systems Security and Privacy, Phenomics, Biology, Entrepreneurship, Real space, FDA, IND, Conference, Safety, Biotechnology, Toronto Office of Emergency Management, Roche, ML, Enamine, Administration, Generative, Ovarian cancer, NF2, International Conference on Machine Learning, Deep learning, Clinical trial, FAP, Proteomics, Trial of the century, Machine learning, Artificial intelligence, Wilson Sonsini Goodrich & Rosati, APC, Pharmaceutical industry, Cryptocurrency, Video game, Bayer, Cyclica, NVIDIA, Recursion

Revenue: Total revenue was $11.0 million for the second quarter of 2023, compared to $7.7 million for the second quarter of 2022.

Key Points: 
  • Revenue: Total revenue was $11.0 million for the second quarter of 2023, compared to $7.7 million for the second quarter of 2022.
  • Research and Development Expenses: Research and development expenses were $55.1 million for the second quarter of 2023, compared to $38.4 million for the second quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $28.3 million for the second quarter of 2023, compared to $21.2 million for the second quarter of 2022.
  • Net Loss: Net loss was $76.7 million for the second quarter of 2023, compared to a net loss of $65.6 million for the second quarter of 2022.

Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds

Retrieved on: 
Tuesday, August 8, 2023
Cloud, Database, Probability, Biochemistry, Matchmaker, Health care, SALT, Chemistry, Protein, Acquisition, NVIDIA, Machine learning, Drug discovery, Recursion, Biology, Entrepreneurship, AI, Real space, AlphaFold, Fine chemical, Cryptocurrency, Enamine, Cyclica

“This achievement represents a significant and exciting step toward achieving our mission of decoding biology and chemistry,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion.

Key Points: 
  • “This achievement represents a significant and exciting step toward achieving our mission of decoding biology and chemistry,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion.
  • “We are excited to collaborate with Recursion to explore the chemical space and support our mission to accelerate drug discovery,” said Andrey Tolmachev, Ph.D., Founder and Owner of Enamine.
  • He continued: “This achievement in the 36 Billion REAL Space is just a start of our journey.
  • The chemical knowledge accumulated at Enamine over its 35-years history allows us to explore trillions of relationships without compromising the high success rate of synthesis.

UL Solutions Issues First Environmental Claim Validation for Biodegradability and Compostability to Cyclica for OLEUM® Leather

Retrieved on: 
Tuesday, June 20, 2023
Windrow composting, Research, UL, Compost, Biodegradation, Environment, Risk management, Landfill, Cyclica

NORTHBROOK, Ill., June 20, 2023 /PRNewswire/ -- UL Solutions, a global leader in applied safety science, today announced that OLEUM® leather by Cyclica, a supplier to the fashion and luxury sectors, is the first to earn an Environmental Claim Validation for biodegradability and compostability. Under UL 1497, Environmental Claim Validation Procedure (ECVP) for Biodegradability and Compostability Correlated to Managed Waste Disposal Methods, UL Solutions has validated that OLEUM has demonstrated at least 90% compostability within one year under aerobic industrial composting conditions.

Key Points: 
  • NORTHBROOK, Ill., June 20, 2023 /PRNewswire/ -- UL Solutions, a global leader in applied safety science, today announced that OLEUM® leather by Cyclica, a supplier to the fashion and luxury sectors, is the first to earn an Environmental Claim Validation for biodegradability and compostability.
  • Under UL 1497, Environmental Claim Validation Procedure (ECVP) for Biodegradability and Compostability Correlated to Managed Waste Disposal Methods, UL Solutions has validated that OLEUM has demonstrated at least 90% compostability within one year under aerobic industrial composting conditions.
  • OLEUM also achieved an Environmental Claim Validation for Bio-based Material when tested to UL 9798, Environmental Claim Validation Procedure (ECVP) for Bio-based Content, demonstrating it contains an average of 73% bio-based content.
  • "With Environmental Claim Validation, UL Solutions is helping manufacturers consider how their products or materials can complete their lifecycle with a focus on environmental impact and enhance the overall product circularity."

UL Solutions Issues First Environmental Claim Validation for Biodegradability and Compostability to Cyclica for OLEUM® Leather

Retrieved on: 
Tuesday, June 20, 2023
Windrow composting, Research, UL, Compost, Biodegradation, Environment, Risk management, Landfill, Cyclica

NORTHBROOK, Ill., June 20, 2023 /PRNewswire/ -- UL Solutions, a global leader in applied safety science, today announced that OLEUM® leather by Cyclica, a supplier to the fashion and luxury sectors, is the first to earn an Environmental Claim Validation for biodegradability and compostability. Under UL 1497, Environmental Claim Validation Procedure (ECVP) for Biodegradability and Compostability Correlated to Managed Waste Disposal Methods, UL Solutions has validated that OLEUM has demonstrated at least 90% compostability within one year under aerobic industrial composting conditions.

Key Points: 
  • NORTHBROOK, Ill., June 20, 2023 /PRNewswire/ -- UL Solutions, a global leader in applied safety science, today announced that OLEUM® leather by Cyclica, a supplier to the fashion and luxury sectors, is the first to earn an Environmental Claim Validation for biodegradability and compostability.
  • Under UL 1497, Environmental Claim Validation Procedure (ECVP) for Biodegradability and Compostability Correlated to Managed Waste Disposal Methods, UL Solutions has validated that OLEUM has demonstrated at least 90% compostability within one year under aerobic industrial composting conditions.
  • OLEUM also achieved an Environmental Claim Validation for Bio-based Material when tested to UL 9798, Environmental Claim Validation Procedure (ECVP) for Bio-based Content, demonstrating it contains an average of 73% bio-based content.
  • "With Environmental Claim Validation, UL Solutions is helping manufacturers consider how their products or materials can complete their lifecycle with a focus on environmental impact and enhance the overall product circularity."

Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 8, 2023
Acceleration, PK, Hemangioma, Partnership, NF2, Therapy, Proxy statement, AXIN1, Roche, Clinical trial, Pharmacokinetics, Intelligence, Research, FAP, History, Genentech, SALT, Chemistry, Development, Bayer, CCM, Patient, Administration, Machine learning, Map, DMPK, Drug discovery, Biology, Entrepreneurship, ESG, APC, Trial of the century, Growth, Ovarian cancer, IND, RBM39, Safety, Software, Pharmaceutical industry, Video game, Rare-earth element, Cyclica, Recursion

Recursion expects both acquisitions to be completed in the second quarter of 2023, subject to applicable closing conditions.

Key Points: 
  • Recursion expects both acquisitions to be completed in the second quarter of 2023, subject to applicable closing conditions.
  • Revenue: Total revenue was $12.1 million for the first quarter of 2023, compared to $5.3 million for the first quarter of 2022.
  • Research and Development Expenses: Research and development expenses were $46.7 million for the first quarter of 2023, compared to $32.4 million for the first quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $22.9 million for the first quarter of 2023, compared to $21.1 million for the first quarter of 2022.

Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities

Retrieved on: 
Monday, May 8, 2023
Acceleration, Learning, Deep learning, Intelligence, Proteome, Research, History, SALT, Drug design, Acquisition, Patient, Machine learning, Map, Polypharmacology, Algorithm, Drug discovery, Biology, Entrepreneurship, AI, Health, Pharmaceutical industry, Medical device, Cyclica, Recursion

“Recursion has pioneered the massive, parallel generation of -omics data with machine learning in order to map and navigate biology to discover new medicines faster.

Key Points: 
  • “Recursion has pioneered the massive, parallel generation of -omics data with machine learning in order to map and navigate biology to discover new medicines faster.
  • “Cyclica and Recursion both believe in the value of industrializing drug discovery,” said Naheed Kurji, CEO and Co-Founder of Cyclica.
  • In certain limited circumstances, Recursion may pay nominal cash consideration to Valence and Cyclica shareholders in lieu of such exchangeable shares or Recursion Class A common stock.
  • Recursion expects both acquisitions to be completed in the second quarter of 2023, subject to applicable closing conditions.

AI in Bio Pharmaceuticals Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 11, 2022
Health, Pharmaceutical, Cloud, Insilico Medicine, Investment, NLP, Cyclica, Telehealth, Health, CSDD, Drug discovery, CMR Surgical, Microsoft, Glass, Partnership, KNIME, FDA, Quantum computing, Therapy, Artificial intelligence, Computer Support Services, Medicine, Hospital, List of life sciences, Novartis, R, Center, Google, CMR, GSK, NVIDIA, Solution, Research, AI, Natural language processing, Pharmaceutical industry, Intelligence, Medical device, Fine chemical, Customer service, Tencent, Pfizer, Nvidia, Erwin Schrödinger

The "AI in Bio Pharmaceuticals" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "AI in Bio Pharmaceuticals" report has been added to ResearchAndMarkets.com's offering.
  • AI is regarded by some top executives at big pharma (Novartis, Pfizer, GSK and others) as a tool to uncover not only new molecules but also new targets.
  • The technology providers in Pharmaceutical Industry are profiled in the report into 6 categories: Artificial Intelligence (R&D Platforms), Quantum Computing, Supporting Services, "Big Tech" Corporations, Autonomous Labs, and Big Data Providers.
  • What are the recent investments, deals, and collaboration for AI in pharma?

OBIO® Secures Funding to Support Health Science Innovators to Build Their Business Capacity in Ontario

Retrieved on: 
Tuesday, April 26, 2022
Health, Other Science, General Health, Research, Science, Biotechnology, CEO, Government, Thought, CAD, Skills Development Fund Corporation, Â, Program, Solution, Ontario Ministry of Citizenship and Immigration, Policy, Industry, Management, Labour, Cyclica

The program was first launched in May 2021 to provide funding to health science companies to support the intellectual property commercialization of Ontario innovations.

Key Points: 
  • The program was first launched in May 2021 to provide funding to health science companies to support the intellectual property commercialization of Ontario innovations.
  • With this new funding, OBIO will continue to address the need for innovative training solutions to help companies gain the critical skills they need to build a global business based in Ontario.
  • The BDSP is unique in that it focuses on enhancing the strategic business development capabilities of management teams in health science companies, says Maura Campbell, CEO and President at OBIO.
  • This OBIO program will ensure Ontario remains at the cutting edge of health sciences technology for years to come.

NUROSENE & CYCLICA PARTNER TO DEVELOP NOVEL DRUGS FOR NEURODEGENERATIVE DISEASES

Retrieved on: 
Thursday, February 10, 2022
Ecosystem, Management, Conversation, Patient, AI, Time, Biomarker, CEO, Legislation, Entrepreneurship, Neurodegeneration, Doctor of Philosophy, SEDAR, Analysis, Solution, IP, Clinical trial, OTC, Risk, Technology, Method, MD, Biotechnology, Association of British HealthTech Industries, Partnership, Disease, Acceleration, CSE, Research, Growth, Multimedia, Drug discovery, News, Intelligence, Biochemistry, Pharmaceutical industry, Fine chemical, Risk management, Cyclica

Nurosene, via NetraMark, will lead in the discovery phase of the research process by identifying specific drug targets.

Key Points: 
  • Nurosene, via NetraMark, will lead in the discovery phase of the research process by identifying specific drug targets.
  • This unique feature fits beautifully with our poly-pharmacological approach at Cyclica, where we can attack disease from multiple approaches simultaneously."
  • Cyclica will use its AI-augmented drug discovery platform to discover novel drug candidates in an efficient manner for drug targets discovered by NetraHealthAtlas.
  • "Working with a leading drug discovery company to tackle neurodegenerative diseases is an exciting opportunity for us.

Cyclica launches Perturba Therapeutics, a spin out from the University of Toronto, creating the next-generation oncology biotech

Retrieved on: 
Wednesday, February 9, 2022
Oncology, Professional Services, Health, Venture Capital, Clinical Trials, Pharmaceutical, Biotechnology, SIMPL, Large-cell lung carcinoma, Biomedical Research, EGFR, Colon, KRAS, Federica Panicucci, AI, Doctor of Philosophy, PPI, SVP, Cancer, Breast, Program, GTPase, Technology, Patient, University, Drug design, CEO, Cystic fibrosis, Health, Genetics, Lung, Entrepreneurship, Research, Center, Inc., Principal, Disease, Lists of diseases, Drug discovery, Biology, Igor Stagljar, MD, Genomics, Fine chemical, Pharmaceutical industry, Vaccine, Cyclica, Homorthodes perturba, Medicine, Perturba, Cyclica, the Stagljar Lab and the Donnelly Centre, PERTURBA, CYCLICA, THE STAGLJAR LAB AND THE DONNELLY CENTRE

Perturba is taking this challenge on by integrating Cyclicas comprehensive AI-augmented proteome-wide drug design technology with two first-in-class live cell-based assays from the Stagljar Lab.

Key Points: 
  • Perturba is taking this challenge on by integrating Cyclicas comprehensive AI-augmented proteome-wide drug design technology with two first-in-class live cell-based assays from the Stagljar Lab.
  • Perturba will initially focus on advancing two EGFR triple mutant inhibitors for non-small cell lung cancer, and four programs targeting small GTPases for various intractable cancers.
  • Naheed Kurji, Co-Founder, CEO and President of Cyclica indicates that More than half of all human disease-related proteins are considered undruggable using conventional approaches.
  • Cyclica will provide initial funding for Perturba and will seek external funding from strategic partners as required.